ArticleF&S reports2025
Optimal timing for triggering oocyte maturation during in vitro fertilization cycles varies between gonadotropin-releasing hormone agonist and human chorionic gonadotropin use.
Article in F&S reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Empty Follicle Syndrome: Current Therapeutic Approaches and the Role of Triggering Agents in Assisted Reproductive Technology.Medical sciences (Basel, Switzerland) · 2026Review
- Reviewing the 36-hour trigger rule through a global lens.F&S reports · 2025Article
- Comparative Effectiveness of Follitropin Delta, Follitropin Alpha, and hMG in ART Cycles: A Single-Center Retrospective Cohort Study With Propensity Score Matching.Reproductive medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the optimal timing for triggering oocyte maturation by evaluating the interval from the trigger to oocyte retrieval and the subsequent in vitro fertilization outcomes. The administration of human chorionic gonadotropin (hCG) or gonadotropin-releasing hormone agonist (GnRHa) is a critical trigger for the final maturation of oocytes within in vitro fertilization cycles. The interval between the trigger and oocyte retrieval has typically been set at 34-40 hours. However, the best timing on the basis of the type of trigger is still unclear. Design: A single-center retrospective cohort study. Subjects: A total of 59,206 oocyte retrieval cycles were investigated at our clinic between April 2010 and March 2024. Cycles with luteinizing hormone surge and those undergoing oocyte retrieval on the day after the trigger were excluded. Exposure: The interval from trigger to oocyte retrieval was from GnRHa or hCG administration to oocyte retrieval initiation. The subjects were categorized into the following two groups according to the type of oocyte maturation trigger used: GnRHa group (buserelin [600 μg] nasal spray) and hCG group (hCG [3,000-10,000 IU] or choriogonadotropin alfa [250 μg] subcutaneously). Main Outcome Measures: The primary outcome measure was the total number of mature metaphase II (MII) oocytes retrieved. Results: The GnRHa trigger group had a higher number of MII oocytes retrieved with a longer interval than with a shorter interval (7.2 ± 6.5 vs. 4.3 ± 5.3), whereas the hCG trigger group had fewer oocytes with a longer interval than with a shorter interval (4.0 ± 4.6 vs. 6.9 ± 5.8). The differences between shorter and longer intervals became more pronounced in older age groups. Although the MII ratio per oocyte did not show significant difference with the interval duration, the blastocyst formation rate and total number of blastocysts were markedly higher when the interval was longer than 36.5 hours in the GnRHa group. Conclusion: The optimal interval varies between the GnRHa trigger and the hCG trigger, with the hCG trigger associated with a shorter interval for obtaining the maximum number of MII oocytes than the GnRHa trigger.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.